Biomarkers of lipid peroxidation in Alzheimer disease (AD): an update
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Increasing evidence suggests that free radical-mediated oxidation of biological substrates is a key feature of Alzheimer’s disease (AD) pathogenesis. While it has long been established that biomarkers of lipid peroxidation (LPO) are elevated in AD brain as well as ventricular CSF postmortem, more recent studies have demonstrated increased LPO biomarkers in postmortem brain from subjects with mild cognitive impairment, the earliest clinically detectable phase of dementia and preclinical AD, the earliest detectable pathological phase. Furthermore, multiple LPO biomarkers are elevated in readily accessible biological fluids throughout disease progression. Collectively, these studies demonstrate that LPO is an early feature during disease progression and may be considered a key pathway for targeted therapeutics as well as an enhancer of diagnostic accuracy for early detection of subjects during the prodromal phase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
Halliwell, B., & Whiteman, M. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705776 · Cited by 2,238
Kohen, R., & Nyska, A. (2002) · Toxicologic Pathology · doi:10.1080/01926230290166724 · Cited by 2,178 · cited 1×
“High metabolic energy demands, elevated transition metal content, and limited antioxidant defenses relative to other organs make the brain a prime target for oxidative damage, mediated by reactive nitrogen species (RNS) and reactive oxygen species (ROS) (reviewed in Kohen and Nyska 2002).”
Oxidative Stress and the Pathogenesis of Alzheimer's Disease
Zhao, Y., & Zhao, B. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/316523 · Cited by 855
Lyras, L., Cairns, N. J., Jenner, A., Jenner, P., & Halliwell, B. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68052061.x · Cited by 531 · cited 3×
“In contrast, mean levels of HPLC-identified TBA– MDA adducts were not significantly different in the frontal lobe (FL), SMTG, middle temporal gyrus (MTG), or HIP of LAD subjects compared to age-matched NC subjects (Lyras et al. 1997).”
InfluentialSultana, R., Perluigi, M., & Butterfield, D. A. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.09.027 · Cited by 478
Increased F 2 ‐isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo
Pratico, D., Lee, V. M.-Y., Trojanowski, J. Q., Rokach, J., & Fitzgerald, G. A. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.15.1777 · Cited by 405 · cited 4×
“However, F2-IsoP isomers were detectable and elevated in the ventricular cerebrospinal fluid (vCSF) of LAD subjects, suggesting that biological fluids in direct contact with the brain reflect ongoing LPO (Pratico et al. 1998).”
InfluentialPadurariu, M., Ciobica, A., Hritcu, L., Stoica, B., Bild, W., & Stefanescu, C. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2009.11.033 · Cited by 378
“Preclinical” AD revisited: Neuropathology of cognitively normal older adults
Schmitt, F. A., Davis, D. G., Wekstein, D. R., Smith, C. D., Ashford, J. W., & Markesbery, W. R. (2000) · Neurology · doi:10.1212/wnl.55.3.370 · Cited by 369
Reed, T., Perluigi, M., Sultana, R., Pierce, W. M., Klein, J. B., Turner, D. M., Coccia, R., Markesbery, W. R., & Butterfield, D. A. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.12.007 · Cited by 257 · cited 3×
“identified seven proteins in the HPG of MCI that exhibited significant increases in HNE modification including lactate dehydrogenase (LDH) and ATP synthase, compared to age-matched NC subjects (Reed et al. 2008).”
InfluentialButterfield, D. A., Reed, T., Perluigi, M., De Marco, C., Coccia, R., Cini, C., & Sultana, R. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2005.12.017 · Cited by 246 · cited 1×
“Similar to extractable levels of HNE, mean levels of total proteinbound HNE are significantly greater in the HPG of PCAD (Bradley et al. 2010), the HPG and IPL of subjects with MCI (Butterfield et al. 2006), and the IPL of EAD subjects (Reed et al. 2009) compared to age-matched NC subjects.”
Perluigi, M., Sultana, R., Cenini, G., Di Domenico, F., Memo, M., Pierce, W. M., Coccia, R., & Butterfield, D. A. (2009) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200800161 · Cited by 196 · cited 3×
“Although protein expression was independent of HNE modification, the activities of ATP synthase and aconitase but not manganese superoxide dismutase (MnSOD) were significantly diminished in LAD subjects compared to age-matched NC subjects (Perluigi et al. 2009).”
InfluentialIncreased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease
Bradley, M. A., Markesbery, W. R., & Lovell, M. A. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.02.016 · Cited by 193 · cited 5×
“Similar to extractable levels of HNE, mean levels of total proteinbound HNE are significantly greater in the HPG of PCAD (Bradley et al. 2010), the HPG and IPL of subjects with MCI (Butterfield et al. 2006), and the IPL of EAD subjects (Reed et al. 2009) compared to age-matched NC subjects.”
InfluentialSelf-citationReed, T. T., Pierce, W. M., Markesbery, W. R., & Butterfield, D. A. (2009) · Brain Research · doi:10.1016/j.brainres.2009.04.009 · Cited by 190
F4 ‐ Isoprostanes as Specific Marker of Docosahexaenoic Acid Peroxidation in Alzheimer's Disease
Nourooz‐Zadeh, J., Liu, E. H. C., Yhlen, B., Änggåard, E. E., & Halliwell, B. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720734.x · Cited by 187
Pulliam, J. F., Jennings, C. D., Kryscio, R. J., Davis, D. G., Wilson, D., Montine, T. J., Schmitt, F. A., & Markesbery, W. R. (2003) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.10069 · Cited by 89 · cited 3×
“1999) as well as mutations in the hereditary hemochromatosis gene HFE (Pulliam et al. 2003).”
Cited by
Breakdown of an Ironclad Defense System: The Critical Role of NRF2 in Mediating Ferroptosis
Anandhan, A., Dodson, M., Schmidlin, C. J., Liu, P., & Zhang, D. D. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.03.011 · Cited by 442
Targeting Nrf2 to Suppress Ferroptosis and Mitochondrial Dysfunction in Neurodegeneration
Abdalkader, M., Lampinen, R., Kanninen, K. M., Malm, T. M., & Liddell, J. R. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00466 · Cited by 423
Mas-Bargues, C., Escrivá, C., Dromant, M., Borrás, C., & Viña, J. (2021) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2021.108941 · Cited by 344
Iron and Alzheimer’s Disease: An Update on Emerging Mechanisms
Lane, D. J. R., Ayton, S., & Bush, A. I. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179944 · Cited by 276
Oxidative stress in alzheimer’s disease: A review on emergent natural polyphenolic therapeutics
Cassidy, L., Fernandez, F., Johnson, J. B., Naiker, M., Owoola, A. G., & Broszczak, D. A. (2020) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2019.102294 · Cited by 275
Metadata
- Authors
- Bradley-Whitman, M. A., & Lovell, M. A.
- Venue
- Archives of Toxicology
- Published
- 2015-04-18
- Volume
- 89
- Issue
- 7
- Pages
- 1035-1044
- ISSN
- 0340-5761 (ISSN-L)
- 1432-0738
- OpenAlex
- W1989420290
- Cited by
- 189
- References
- 17
- FWCI
- 5.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.